Survivin mRNA antagonists using locked nucleic acid, potential for molecular cancer therapy

被引：10

作者：

Fisker, Niels ^{[1
]}

Westergaard, Majken ^{[1
]}

Hansen, Henrik Frydenlund ^{[1
]}

Hansen, Jens Bo ^{[1
]}

机构：

[1] Santaris Pharma AS, DK-2970 Horsholm, Denmark

来源：

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS | 2007年 / 26卷 / 10-12期

关键词：

locked nucleic acid; survivin; mRNA; LNA; antisense;

D O I：

10.1080/15257770701542132

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

We have investigated the effects of different locked nucleic acid modified antisense mRNA antagonists against Survivin in a prostate cancer model. These mRNA antagonists were found to be potent inhibitors of Survivin expression at low nanomolar concentrations. Additionally there was a pronounced synergistic effect when combining the mRNA antagonists against Survivin with the chemotherapeutic Taxol. This effect was demonstrated at concentrations of antagonists far lower than any previously demonstrated, indicating the high potential of locked nucleic acid for therapeutic use. Further characterisations in vivo are ongoing.

引用

页码：1427 / 1430

页数：4

共 5 条

[1] Validating survivin as a cancer therapeutic target [J].